231 related articles for article (PubMed ID: 31605350)
41. ASO Author Reflections: The Impact of Circular FAT1 in Esophageal Squamous Cell Carcinoma: Investigation of a Novel Tumor Suppressor.
Takaki W; Konishi H; Shoda K; Otsuji E
Ann Surg Oncol; 2022 Dec; 29(Suppl 3):579-580. PubMed ID: 34665360
[No Abstract] [Full Text] [Related]
42. ASO Author Reflections: Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy.
Sugimura K; Miyata H; Kanemura T; Takeoka T; Sugase T; Yamamoto M; Shinnno N; Hara H; Omori T; Motoori M; Ohue M; Yano M
Ann Surg Oncol; 2023 Jul; 30(7):4203-4204. PubMed ID: 37029864
[No Abstract] [Full Text] [Related]
43. An insufficient number of examined lymph nodes may offset the survival benefit from neoadjuvant therapy in esophageal squamous cell carcinoma.
Yang YS; Hu WP; Wang WP; Yuan Y; Chen LQ
Surgery; 2019 Mar; 165(3):664-667. PubMed ID: 30193735
[No Abstract] [Full Text] [Related]
44. Numeric pathologic lymph node classification shows prognostic superiority to topographic pN classification in esophageal squamous cell carcinoma.
Sugawara K; Yamashita H; Uemura Y; Mitsui T; Yagi K; Nishida M; Aikou S; Mori K; Nomura S; Seto Y
Surgery; 2017 Oct; 162(4):846-856. PubMed ID: 28739092
[TBL] [Abstract][Full Text] [Related]
45. ASO Author Reflections: Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Chan WL
Ann Surg Oncol; 2023 Feb; 30(2):871-872. PubMed ID: 36380255
[No Abstract] [Full Text] [Related]
46. ASO Author Reflections: Biomarkers for Neoadjuvant Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma.
Okumura H; Noda M; Natsugoe S
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):715-716. PubMed ID: 30288651
[No Abstract] [Full Text] [Related]
47. Reply to: Insufficient number of examined lymph nodes may offset the survival benefit from neoadjuvant therapy in esophageal squamous cell carcinoma.
Franko J; McAvoy S
Surgery; 2019 Mar; 165(3):664-667. PubMed ID: 30467040
[No Abstract] [Full Text] [Related]
48. ASO Author Reflections: Response to Neoadjuvant Chemotherapy Strengthens the Prognostic Impact of Pathological Stage for Esophageal Squamous Cell Carcinoma.
Matsuda S; Kawakubo H; Okamura A; Takahashi K; Toihata T; Takemura R; Mayanagi S; Takeuchi H; Watanabe M; Kitagawa Y
Ann Surg Oncol; 2021 Dec; 28(13):8448-8449. PubMed ID: 34143335
[No Abstract] [Full Text] [Related]
49. ASO Author Reflections: Prognostic Significance of Kallikrein-Related Peptidase 13 Induction After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
Shimomura A; Yamada K; Kawamura YI
Ann Surg Oncol; 2024 Jan; 31(1):243-244. PubMed ID: 37851200
[No Abstract] [Full Text] [Related]
50. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
[TBL] [Abstract][Full Text] [Related]
51. Outcomes of operation for esophageal squamous cell carcinoma: Which approach is best?
Ferraris VA
J Thorac Cardiovasc Surg; 2015 Apr; 149(4):1016-7. PubMed ID: 25659854
[No Abstract] [Full Text] [Related]
52. Prognosis of patients with esophageal squamous cell carcinoma after esophagectomy using the log odds of positive lymph nodes.
Wu SG; Sun JY; Yang LC; Zhou J; Li FY; Li Q; Lin HX; Lin Q; He ZY
Oncotarget; 2015 Nov; 6(34):36911-22. PubMed ID: 26426993
[TBL] [Abstract][Full Text] [Related]
53. ASO Author Reflections: Comparison of Aggressive Planned Salvage Surgery versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma.
Shiraishi O
Ann Surg Oncol; 2021 Oct; 28(11):6376-6377. PubMed ID: 33830358
[No Abstract] [Full Text] [Related]
54. [Modified (Wu's) esophagectomy for a huge thoracic esophageal squamous cell carcinoma 18.3 cm in length].
Wu X; Zhang ZZ; Liu NB; Zhang JH
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(7):1018-20. PubMed ID: 27435787
[TBL] [Abstract][Full Text] [Related]
55. Risk-stratified clinical management of superficially invasive esophageal squamous cell carcinoma after endoscopic resection: finding the sweet spot.
Jansen M; Bergman J
Endoscopy; 2018 Jul; 50(7):655-656. PubMed ID: 29949821
[No Abstract] [Full Text] [Related]
56. ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma.
Xie C; Hu Y; Han L; Fu J; Vardhanabhuti V; Yang H
Ann Surg Oncol; 2022 Dec; 29(13):8127-8128. PubMed ID: 35933539
[No Abstract] [Full Text] [Related]
57. ASO Author Reflections: Perineural Invasion in pN0M0 Esophageal Squamous Cell Carcinoma: Let Pathology Strengthen the Clinical Oncology Practice.
Guo YN; Su M
Ann Surg Oncol; 2020 Oct; 27(11):4382-4383. PubMed ID: 32632885
[No Abstract] [Full Text] [Related]
58. Sweet Versus Ivor-Lewis: Is It Time To Draw a Conclusion?
Shi H; Han Y; Peng L
Ann Surg; 2018 Aug; 268(2):e34-e35. PubMed ID: 29095197
[No Abstract] [Full Text] [Related]
59. Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma.
Lin CS; Cheng CT; Liu CY; Lee MY; Hsiao MC; Shih CH; Liu CC
Ann Thorac Surg; 2015 Jul; 100(1):278-86. PubMed ID: 26002444
[TBL] [Abstract][Full Text] [Related]
60. [Clinical value of para-recurrent laryngeal nerve lymphadenectomy for middle thoracic esophageal squamous cell carcinoma].
Wang Z; Liu S
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Sep; 18(9):867-70. PubMed ID: 26404679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
